research use only
Cat.No.E2914
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other Casein Kinase Inhibitors | Silmitasertib (CX-4945) Silmitasertib (CX-4945) sodium salt D 4476 TBB IC261 PF-670462 Ellagic Acid hydrate TTP 22 Longdaysin PF 4800567 |
| Molecular Weight | 319.14 | Formula | C12H12Cl2N2O4 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 53-85-0 | -- | Storage of Stock Solutions |
|
|
|
In vitro |
DMSO
: 64 mg/mL
(200.53 mM)
Ethanol : 5 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Targets/IC50/Ki |
Casein Kinase 2
|
References |
|
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05051605 | Recruiting | Liver Transplant |
Ain Shams University |
September 15 2021 | -- |
| NCT05040854 | Recruiting | Inflammatory Bowel Diseases |
Centro Hospitalar Tondela-Viseu |
July 1 2021 | -- |
| NCT03861962 | Not yet recruiting | Organ Transplantation |
Assistance Publique - Hôpitaux de Paris |
May 2019 | -- |
| NCT03506035 | Unknown status | Rheumatoid Arthritis |
Corporacion Parc Tauli |
September 1 2018 | -- |
| NCT05284929 | Unknown status | Pemphigus|Bullous Pemphigoid|Stevens-Johnson Syndrome|Toxic Epidermal Necrolyses |
Sechenov University|Pirogov Russian National Research Medical University |
May 17 2017 | -- |
| NCT05342948 | Completed | Recurrent Pregnancy Loss |
Aalborg University Hospital |
January 1 2016 | -- |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.